[1]裴 婕,路 云,周 萍,等.瑞典基本药物目录的发展及启示[J].卫生经济研究,2018,(08):46-48.
　PEI Jie,LU Yun,ZHOU Ping,et al.The development and enlightenment of essential drug list in Sweden[J].Journal Press of Health Economics Research,2018,(08):46-48.
点击复制

瑞典基本药物目录的发展及启示
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2018年08期
页码:
46-48
栏目:
他山之石
出版日期:
2018-08-01

文章信息/Info

Title:
The development and enlightenment of essential drug list in Sweden
作者:
裴 婕1; 路 云1; 周 萍1; 常 峰1
1.中国药科大学国际医药商学院，江苏 南京 211198
Author(s):
PEI Jie;  LU Yun;  ZHOU Ping;  CHANG Feng
School of international pharmaceutical business, China Pharmaceutical University, Nanjing Jiangsu 211198，China
关键词:
基本药物目录; 基本药物; 瑞典
Keywords:
Essential drugs list;  Essential drugs;  Sweden
分类号:
R95
文献标志码:
A
摘要:
瑞典作为唯一建立基本药物目录的发达国家，其基本药物目录较为成熟。本文对瑞典基本药物目录的现状、发展变化以及推行经验进行研究，提出实施评估反馈机制、增加药品使用建议、引入药品“风险分担协议”、探索省市两级目录等建议，为完善和修订我国基本药物目录提供参考。
Abstract:
Sweden is the only developed country where the essential drug list is established, and its essential drug list is more mature than of other countries. This paper analyzed the current situation, development and experience of Swedish essential drugs list. Some suggestions have been put forward to improve and revise the essential drug list in China, including for example implementing evaluation feedback mechanism, increasing drug use suggestions, introducing drug 'risk sharing agreement', and exploring the provincial and municipal essential drug list.

参考文献/References:

[1] The Dental and Pharmaceutical Benefits Agency.PPRI Pharma Profile 2017 Sweden[EB/OL].[2018-02-13].PPRI Pharma Profile 2017 Sweden Page 56.
[2] Essential medicines selection-Sweden [EB/OL].[2018-02-13].http:// www.who.int/selection_medicines/country_lists/swe/en/.
[3] Eriksen, Jaran; Karolinska Instituet, Division of Clinical Pharmacology, Department of Laboratory Medicine, etc.“High adherence to the “Wise List” treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines”[EB/OL].[2018-02-13]. Published on BMJ Open 2016-Oct.
[4] 常峰，崔鹏磊，张舰云，等.全球视角下药品风险分担协议政策分析[J].卫生经济研究,2016(8):39-44.

相似文献/References:

[1]何常楠,傅鸿鹏.20种基本药物的集中采购价格分析[J].卫生经济研究,2016,(08):44.
[2]赵 静.应用层次分析法优化基本药物遴选的研究[J].卫生经济研究,2016,(12):13.
[3]王文杰,毛宗福,肖琳琪,等.贫困地区基层医疗机构基本药物供应保障研究[J].卫生经济研究,2018,(02):35.
[4]杜雯雯,徐 伟,李孟林.南京市各级医疗机构用药结构和用药衔接性研究[J].卫生经济研究,2018,(09):26.
　DU Wen-wen,XU Wei,LI Meng-lin.Study on the Structure and Coherence of Drug Use in Medical Institutions at All Levels in Nanjing[J].Journal Press of Health Economics Research,2018,(08):26.
[5]李晓春,侯艳红.国家基本药物制度的完善及走向[J].卫生经济研究,2018,(12):34.
　LI Xiao-chun,HOU Yan-hong.The Improvement and Trend of the National Basic Drug System[J].Journal Press of Health Economics Research,2018,(08):34.
[6]吴玉霞,徐 伟,蔡功杰,等.基本药物可获得性影响因素研究——基于25省监测点数据的实证分析[J].卫生经济研究,2018,(12):37.
　WU Yu-xia,XU Wei,CAI Gong-jie,et al.Study on the Factors Affecting the Availability of Essential Drugs——An Empirical Analysis Based on Data from 25 Provinces[J].Journal Press of Health Economics Research,2018,(08):37.
[7]杜雯雯,徐 伟,蔡功杰.我国基本药物全额保障的实现路径研究[J].卫生经济研究,2018,(12):40.
　DU Wen-wen,XU Wei,CAI Gong-jie.Study on the Realizing Path of the Full Guarantee of Essential Medicines in China[J].Journal Press of Health Economics Research,2018,(08):40.
[8]张闪闪,吴 天,张 冉,等.2018年版《国家基本药物目录》调整解读[J].卫生经济研究,2019,(06):47.
　ZHANG Shan-shan,WU Tian,ZHANG Ran,et al.Interpretation of the 2018 Edition of the National Essential Drugs List[J].Journal Press of Health Economics Research,2019,(08):47.
[9]胡善联.2019年版世界卫生组织 基本药物目录的创新及特点[J].卫生经济研究,2019,(09):3.
　HU Shan-lian.Innovation and Characteristics of WHO Essential Medicines Model List 2019[J].Journal Press of Health Economics Research,2019,(08):3.
[10]刘朝一,徐 伟,许正圆.基于价格指数的基本药物价格水平研究——以江苏省抗感染类药物为例[J].卫生经济研究,2020,(08):38.
　LIU Chao-yi,XU Wei,XU Zheng-yuan.Study on the Price Level of Essential Drugs Based on Price Index—— Take Anti-infective drugs in Jiangsu Province as an Example[J].Journal Press of Health Economics Research,2020,(08):38.

更新日期/Last Update: 2018-07-30